Cardiome Announces Update in Commercialization Partnership for BRINAVESSâ„¢ in Select European Markets

[PR Newswire] – VANCOUVER, Feb. 19, 2014 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that pursuant to its agreement of July 2013, the company has begun shipping BRINAVESSâ„¢ (vernakalant intravenous) to AOP Orphan Pharm more

View todays social media effects on CRME

View the latest stocks trending across Twitter. Click to view dashboard

See who Cardiome is hiring next, click here to view